Aldeyra eyes 2 PDUFA dates, 3 sets of trial results in Q2

 

• Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the Second Quarter of 2023
• Top-Line Results from the Phase 2 Clinical Trial of ADX-629 in Chronic Cough Expected in the Second Quarter of 2023
• Top-Line Results from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis Expected in the Second Quarter of 2023
• NDA Priority Review PDUFA Date for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma is June 21, 2023
• NDA PDUFA Date for Reproxalap for the Treatment of Dry Eye Disease is November 23, 2023
• Cash and Cash Equivalents of $165.0 Million as of March 31, 2023

https://www.biospace.com/article/releases/aldeyra-therapeutics-reports-first-quarter-2023-financial-results-and-recent-corporate-highlights/